In last trading session, 9 Meters Biopharma Inc. (NASDAQ:NMTR) saw 1.58 million shares changing hands with its beta currently measuring -2.17. Company’s recent per share price level of $0.21 trading at -$0.01 or -6.00% at ring of the bell on the day assigns it a market valuation of $52.30M. That closing price of NMTR’s stock is at a discount of -595.24% from its 52-week high price of $1.46 and is indicating a premium of 4.76% from its 52-week low price of $0.20. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.89 million shares which gives us an average trading volume of 3.63 million if we extend that period to 3-months.
For 9 Meters Biopharma Inc. (NMTR), analysts’ consensus is at an average recommendation of a Buy while assigning it a mean rating of 1.80. Splitting up the data highlights that, out of 6 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 5 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.04 in the current quarter.
9 Meters Biopharma Inc. (NASDAQ:NMTR) trade information
Upright in the red during last session for losing -6.00%, in the last five days NMTR remained trading in the red while hitting it’s week-highest on Monday, 09/19/22 when the stock touched $0.21 price level, adding 12.5% to its value on the day. 9 Meters Biopharma Inc.’s shares saw a change of -78.55% in year-to-date performance and have moved -8.98% in past 5-day. 9 Meters Biopharma Inc. (NASDAQ:NMTR) showed a performance of -22.26% in past 30-days. Number of shares sold short was 5.14 million shares which calculate 0.6 days to cover the short interests.
9 Meters Biopharma Inc. (NMTR) estimates and forecasts
Statistics highlight that 9 Meters Biopharma Inc. is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -62.58% of value to its shares in past 6 months, showing an annual growth rate of -20.00% while that of industry is 1.80. Apart from that, the company came lowering its revenue forecast for fiscal year 2022. The company is estimating its revenue growth to decrease by -33.30% in the current quarter and calculating 20.00% increase in the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 57.80% during past 5 years.
9 Meters Biopharma Inc. is more likely to be releasing its next quarterly report on November 15 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
9 Meters Biopharma Inc. (NASDAQ:NMTR)’s Major holders
Insiders are in possession of 4.01% of company’s total shares while institution are holding 27.63 percent of that, with stock having share float percentage of 28.78%. Investors also watch the number of corporate investors in a company very closely, which is 27.63% institutions for 9 Meters Biopharma Inc. that are currently holding shares of the company. Adage Capital Partners GP L.L.C. is the top institutional holder at NMTR for having 15.0 million shares of worth $8.99 million. And as of Mar 30, 2022, it was holding 5.79% of the company’s outstanding shares.
The second largest institutional holder is Blackrock Inc., which was holding about 13.99 million shares on Mar 30, 2022. The number of shares represents firm’s hold over 5.40% of outstanding shares, having a total worth of $8.38 million.
On the other hand, Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund are the top two Mutual Funds which own company’s shares. As of Mar 30, 2022, the former fund manager was holding 6.73 million shares of worth $4.03 million or 2.60% of the total outstanding shares. The later fund manager was in possession of 3.04 million shares on Mar 30, 2022, making its stake of worth around $1.82 million in the company or a holder of 1.17% of company’s stock.